Sign inJoin free
Decision 02

Is it a good business

Quality — cash generation, balance sheet, moat, management. The judgement that separates a name from a business.

Learn the concepts

Explainer

The art or science of investment decision making

Investment decisions shouldn’t be driven by emotion or FOMO, but by thoughtful analysis and valuation. In this article, I share my approach to evaluating businesses, understanding uncertainty, and finding undervalued opportunities that others might overlook.

Neil Woodford · 28 Nov 2024

In practice

The Show · S2 Ep 2

London Isn't Dying — It's On Sale. Here's Where To Look

UK stocks are being taken private at a record pace: this year, takeover bids for London-listed companies have run at roughly £60bn against under £600m raised in new IPOs, and Neil Woodford argues that this wave of M&A is the clearest sign in years that UK equities are undervalued. In this episode, Woodford and Jon Adair break down why the FTSE and London stock market trade at such a deep discount to the US, what a 75% takeover premium reveals about UK share prices, whether British stocks are cheap or a value trap, and where Woodford sees value across UK banks, oil and housebuilders.

33 min · video + audio · 10 Jul 2026
The Show · S1 Ep 39

Why Britain Can't Build a Trillion Dollar Giant

This week, a single American memory chip company became worth more than AstraZeneca, HSBC and Shell combined. So why has Britain never built one of its own?

31 min · video + audio · 29 May 2026
Sector

Sector update: Semiconductors

AI demand is soaring. Inventories are clearing. Pricing power is returning. And that’s showing up in the numbers — not just in Nvidia, but in less obvious names like STMicro and TSMC.

Neil Woodford · 18 Jun 2025
SectorPaid

UK Housebuilders Update

UK housebuilders are out of favour. But that’s exactly when companies often offer the best long-term opportunities.

Neil Woodford · 11 Jun 2025
Stock deep dive

BioNTech: Broader appeal

After years of weak performance in the biotech sector, BioNTech has secured a landmark partnership with Bristol Myers Squibb, worth up to $11.1bn. This deal is a major validation of BioNTech’s cancer pipeline and supports Neil’s thesis: the market is undervaluing mature biotech firms. BioNTech was up 20% yesterday on the news.

Neil Woodford · 3 Jun 2025
SectorPaid

UK banks update

Strong Q1 results from two UK banks. Both beat expectations, delivered solid ROEs, and are still trading well below fair value — despite the usual tariff-related over caution.

Neil Woodford · 2 May 2025
Stock deep divePaid

Barclays: beating expectations

Barclays’ Q1 results back up what I said — the market’s reaction to the tariffs was overdone. Strong numbers, solid returns, and still well below book.

Neil Woodford · 30 Apr 2025
Stock deep divePaid

Next: confounding the sceptics, again

Next’s results and outlook were better than expected — again. The transformation is working, and I suspect the best is still to come.

Neil Woodford · 27 Mar 2025
Macro

How Did We Get Here?

Trump’s presidency has already sparked dramatic changes—not just in politics but in the corporate world. From free speech to ESG and DEI, this article explores how his election is reshaping global business culture and raising questions about honesty, accountability, and the future of capitalism.

Neil Woodford · 22 Jan 2025
Sector

Copy Nothing, Risk Everything?

Jaguar’s bold rebrand and shift to an all-electric lineup by 2026 have sparked intrigue and criticism. European carmakers are racing to adapt to EVs, fierce competition, and shifting customer attitudes.

Neil Woodford · 22 Nov 2024